Double-blinded, randomized trial in severe community acquired pneumonia patients with severe sepsis investigating the safety and efficacy of co-administration of iloprost and ascending doses of eptifibatide compared to low-molecular-weight heparin.

Trial Profile

Double-blinded, randomized trial in severe community acquired pneumonia patients with severe sepsis investigating the safety and efficacy of co-administration of iloprost and ascending doses of eptifibatide compared to low-molecular-weight heparin.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 07 Dec 2016

At a glance

  • Drugs Eptifibatide (Primary) ; Iloprost (Primary) ; Enoxaparin sodium
  • Indications Embolism and thrombosis; Septic shock
  • Focus Therapeutic Use
  • Sponsors Thrombologic
  • Most Recent Events

    • 01 Jun 2013 Status changed from recruiting to discontinued as reported by European Clinical Trials Database.
    • 29 Sep 2012 Planned End Date changed from 8 Aug 2013 to 8 May 2013 as reported by European Clinical Trials Database
    • 24 Feb 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top